Sector: Pharmaceutical Preparations · Industry: Biotechnology · Exchange: NYSE
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Headquarters: Potomac, MD, US · Employees: 70 · Website: https://igcpharma.com
IGC Pharma, Inc. (IGC) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on NYSE. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Search companies · Macro trends · Industries · Product categories · Baskets